Valute / ALLO
ALLO: Allogene Therapeutics Inc
1.13
USD
0.05
(4.24%)
Il tasso di cambio ALLO ha avuto una variazione del -4.24% per oggi. Durante la giornata, lo strumento è stato scambiato ad un minimo di 1.11 e ad un massimo di 1.20.
Segui le dinamiche di Allogene Therapeutics Inc. Le quotazioni in tempo reale aiutano a reagire velocemente alle variazioni di mercato. Scorrendo tra i diversi timeframe, è possibile monitorare le tendenze e le dinamiche dei tassi di cambio di minuti, ore, giorni, settimane e mesi. Utilizza queste informazioni per prevedere i cambiamenti del mercato e prendere decisioni di trading consapevoli.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ALLO News
- Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
- Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)
- Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
- Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
- Allogene Q2 Cash Tops $300 Million
- Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts
- Allogene stock continues ALPHA3 trial with standard FC regimen after safety event
- Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment
- This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics (NASDAQ:ALLO), AvalonBay Communities (NYSE:AVB)
- Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Allogene Therapeutics (NASDAQ:ALLO)
- Adicet Bio stock rating initiated at Buy by H.C. Wainwright
- Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
- Allogene Therapeutics at Jefferies Conference: Delays and Optimism
- Citi maintains buy rating on Allogene stock following ASCO data
- H.C. Wainwright maintains buy rating on Allogene stock after ASCO update
- Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- Citizens JMP highlights key ASCO presentations
- Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
- Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner
- Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene shares update on CAR T-cell therapies at ASCO meeting
- Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays
- Abrdn Life Sciences Investors Q4 2024 Commentary (NYSE:HQL)
Intervallo Giornaliero
1.11
1.20
Intervallo Annuale
0.86
3.78
- Chiusura Precedente
- 1.18
- Apertura
- 1.18
- Bid
- 1.13
- Ask
- 1.43
- Minimo
- 1.11
- Massimo
- 1.20
- Volume
- 1.878 K
- Variazione giornaliera
- -4.24%
- Variazione Mensile
- -5.83%
- Variazione Semestrale
- -39.25%
- Variazione Annuale
- -56.37%
30 agosto, sabato